EE464 The Cost-Effectiveness of Subcutaneous Semaglutide 2.4MG Injection in the Management of Obesity in Canada Using the Core Obesity Model

The objective of this study was to assess the cost-effectiveness of semaglutide 2.4mg versus diet and exercise (D&E) in Canada using the Core Obesity Model (COM) and clinical outcomes from the STEP 1 and 2 studies, both of which demonstrated significantly greater weight loss with subcutaneous semaglutide 2.4mg injection versus D&E alone.